Hc Advisors, LLC Celldex Therapeutics, Inc. Transaction History

Hc Advisors, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 08, 2023	SELL	$27.78 - $45.38 $188,626 - $308,130	-6,790 Reduced 55.95%	5,345 $238,000
Q3 2022 Nov 10, 2022	BUY	$22.7 - $37.57 $102,377 - $169,440	4,510 Added 59.15%	12,135 $341,000
Q2 2022 Aug 08, 2022	SELL	$20.5 - $37.33 $1,025 - $1,866	-50 Reduced 0.65%	7,625 $206,000
Q1 2022 May 06, 2022	SELL	$27.64 - $39.32 $14,041 - $19,974	-508 Reduced 6.21%	7,675 $261,000
Q4 2021 Feb 02, 2022	BUY	$35.68 - $56.27 $96,121 - $151,591	2,694 Added 49.08%	8,183 $316,000
Q3 2021 Oct 29, 2021	SELL	$28.95 - $55.99 $26,836 - $51,902	-927 Reduced 14.45%	5,489 $296,000
Q2 2021 Aug 09, 2021	BUY	$20.71 - $35.37 $132,875 - $226,933	6,416 New	6,416 $215,000
Q1 2021 May 07, 2021	SELL	$16.19 - $29.91 $239,466 - $442,398	-14,791 Closed	0 $0
Q4 2020 Feb 08, 2021	BUY	$14.99 - $22.75 $33,127 - $50,277	2,210 Added 17.57%	14,791 $259,000
Q3 2020 Nov 04, 2020	BUY	$9.65 - $15.19 $121,406 - $191,105	12,581 New	12,581 $187,000

207

67.3M

1.69M

980K

Ticker CLDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,772,400
Market Cap $1.26B
Description
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...

Get notified when there are updates to the investment portfolio of Hc Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Hc Advisors, LLC with notifications on news.